A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling

Oncogene

Volumn 30, Issue 30, 2011, Pages 3370-3380

  Clem, B F ^a,b   Clem, A L ^a,b   Yalcin, A ^a,b,c   Goswami, U ^a,b   Arumugam, S ^b   Telang, S ^a,b   Trent, J O ^a,b   Chesney, J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

chemotherapy; choline kinase; in silico; metabolism; phosphocholine

Indexed keywords

CHOLINE KINASE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (3,5 DIMETHYLPHENYL) 2 [[5 (4 ETHYLPHENYL) 1H 1,2,4 TRIAZOL 3 YL]SULFANYL] ACETAMIDE; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLCHOLINE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG TUMOR; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SECOND MESSENGER; SIGNAL TRANSDUCTION; STEADY STATE; TUMOR XENOGRAFT;

ACETAMIDES; ACTINS; ANIMALS; CELL MEMBRANE; CELL PROLIFERATION; CHOLINE KINASE; COMPUTATIONAL BIOLOGY; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960835666     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.51     Document Type: Article

References (54)

1. Ackerstaff E, Glunde K, Bhujwalla ZM. (2003). Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90: 525-533. (Pubitemid 37243700)
2. Aoyama C, Liao H, Ishidate K. (2004). Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281. (Pubitemid 38299195)
3. Buchanan FG, McReynolds M, Couvillon A, Kam Y, Holla VR, Dubois RN et al. (2005). Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci USA 102: 1638-1642. (Pubitemid 40209220)
4. Chua BT, Gallego-Ortega D, Ramirez de Molina A, Ullrich A, Lacal JC, Downward J. (2009). Regulation of Akt(ser473) phosphory-lation by Choline kinase in breast carcinoma cells. Mol Cancer 8: 131.
5. Chung T, Huang JS, Mukherjee JJ, Crilly KS, Kiss Z. (2000). Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. Cell Signal 12: 279-288. (Pubitemid 30261542)
6. Degani H, Horowitz A, Itzchak Y. (1986). Breast tumors: evaluation with P-31 MR spectroscopy. Radiology 161: 53-55. (Pubitemid 16031426)
7. Eliyahu G, Kreizman T, Degani H. (2007). Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 120: 1721-1730. (Pubitemid 46402874)
8. Exton JH. (1990). Signaling through phosphatidylcholine breakdown. J Biol Chem 265: 1-4.
9. Fan TW, Kucia M, Jankowski K, Higashi RM, Ratajczak J, Ratajczak MZ et al. (2008). Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes. Mol Cancer 7: 79.
10. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945. (Pubitemid 33101594)
11. Foster DA, Xu L. (2003). Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1: 789-800. (Pubitemid 37174450)
12. Glunde K, Bhujwalla ZM. (2007). Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol 8: 855-857. (Pubitemid 47488058)
13. Glunde K, Raman V, Mori N, Bhujwalla ZM. (2005). RNA interference- mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043. (Pubitemid 41713374)
14. Glunde K, Shah T, Winnard Jr PT, Raman V, Takagi T, Vesuna F et al. (2008). Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res 68: 172-180. (Pubitemid 351380118)
15. Ha KS, Exton JH. (1993). Activation of actin polymerization by phosphatidic acid derived from phosphatidylcholine in IIC9 fibroblasts. J Cell Biol 123: 1789-1796. (Pubitemid 24012934)
16. Hancock JF. (2007). PA promoted to manager. Nat Cell Biol 9: 615-617. (Pubitemid 47214719)
17. Hernandez-Alcoceba R, Fernandez F, Lacal JC. (1999). In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 59: 3112-3118. (Pubitemid 29316010)
18. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA et al. (1997). Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15: 2289-2301. (Pubitemid 27496980)
19. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S et al. (2008). Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88. (Pubitemid 350286175)
20. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S et al. (2005). Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65: 9369-9376. (Pubitemid 41508005)
21. Irwin JJ, Shoichet BK. (2005). ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45, 177-182. (Pubitemid 40736970)
22. Jain AN. (2007). Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21: 281-306. (Pubitemid 46630055)
23. Jimenez B, del Peso L, Montaner S, Esteve P, Lacal JC. (1995). Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 57: 141-149.
24. Kent C. (1995). Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 64: 315-343.
25. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H et al. (2008). Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclini-cal mouse model. J Clin Invest 118: 3051-3064.
26. Ko KW, Cook HW, Vance DE. (1986). Reduction of phosphatidyl-choline turnover in a Nb 2 lymphoma cell line after prolactin treatment. A novel mechanism for control of phosphatidylcholine levels in cells. J Biol Chem 261: 7846-7852. (Pubitemid 17208713)
27. Li G, D'Souza-Schorey C, Barbieri MA, Cooper JA, Stahl PD. (1997). Uncoupling of membrane ruffling and pinocytosis during Ras signal transduction. J Biol Chem 272: 10337-10340. (Pubitemid 27181029)
28. Malito E, Sekulic N, Too WC, Konrad M, Lavie A. (2006). Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine. J Mol Biol 364: 136-151. (Pubitemid 44649251)
29. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW et al. (2007). Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47: 64-103. (Pubitemid 47302072)
30. Neeman M, Degani H. (1989). Early estrogen-induced metabolic changes and their inhibition by actinomycin D and cycloheximide in human breast cancer cells: 31P and 13C NMR studies. Proc Natl Acad Sci USA 86: 5585-5589. (Pubitemid 19185589)
31. Onodera K, Okubo A, Yasumoto K, Suzuki T, Kimura G, Nomoto K. (1986). 31P nuclear magnetic resonance analysis of lung cancer: the perchloric acid extract spectrum. Jpn J Cancer Res 77: 1201-1206. (Pubitemid 17233894)
32. Ramirez De Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D et al. (2004a). Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 64: 6732-6739. (Pubitemid 39297936)
33. Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. (2005). Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 65: 5647-5653. (Pubitemid 40911165)
34. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F et al. (2002a). Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 21: 4317-4322. (Pubitemid 34753838)
35. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. (2002b). Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 21: 937-946. (Pubitemid 34146307)
36. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F et al. (2002c). Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296: 580-583.
37. Ramirez de Molina A, Rodriguez-Gonzalez A, Lacal JC. (2004b). From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 206: 137-148. (Pubitemid 38317284)
38. Rizzo M, Romero G. (2002). Pharmacological importance of phospho-lipase D and phosphatidic acid in the regulation of the mitogen-activated protein kinase cascade. Pharmacol Ther 94: 35-50. (Pubitemid 34615956)
39. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA et al. (1999). Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem 274: 1131-1139. (Pubitemid 29058090)
40. Rizzo MA, Shome K, Watkins SC, Romero G. (2000). The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem 275: 23911-23918. (Pubitemid 30624680)
41. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J et al. (2003). Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 22: 8803-8812. (Pubitemid 38021496)
42. Roovers K, Assoian RK. (2003). Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases. Mol Cell Biol 23: 4283-4294. (Pubitemid 36666430)
43. Salmena L, Carracedo A, Pandolfi PP. (2008). Tenets of PTEN tumor suppression. Cell 133: 403-414. (Pubitemid 351622014)
44. Scales SJ, Scheller RH. (1999). Lipid membranes shape up. Nature 401: 123-124. (Pubitemid 29436301)
45. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. (1987). Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 71: 297-304. (Pubitemid 17051732)
46. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW et al. (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25: 7225-7234. (Pubitemid 44809088)
47. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. (2008). Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic Acid-a competition with rapamycin. Mol Cell Biol 29: 1411-1420.
48. Uchida T. (1996). Stimulation of phospholipid synthesis in HeLa cells by epidermal growth factor and insulin: activation of choline kinase and glycerophosphate acyltransferase. Biochim Biophys Acta 1304: 89-104. (Pubitemid 26414382)
49. Vieira AV, Lamaze C, Schmid SL. (1996). Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274: 2086-2089. (Pubitemid 27020702)
50. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. (2000). Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62. (Pubitemid 30609563)
51. Warden CH, Friedkin M. (1985). Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 260: 6006-6011. (Pubitemid 15072502)
52. Wu G, Aoyama C, Young SG, Vance DE. (2008). Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem 283: 1456-1462.
53. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J et al. (2009). Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 29: 139-149.
54. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. (2007). Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9: 706-712.